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ABSTRACT  
 Ranking as the fourth commonest cancer, esophageal squamous cell carcinoma 
(ESCC) represents one of the leading causes of cancer death in China. One of the main 
reasons for the low survival rate is that neoplasms in esophagus are not detected until they 
have invaded into surrounding tissues or spread throughout the body at advanced stages. A 
better understanding of the malignant mechanism and early diagnosis are important for 
fighting ESCC. In this study, we used proteomics to analyze ESCC tissues, aiming at 
defining the proteomic features implicated in the multistage progression of esophageal 
carcinogenesis. Proteins that exhibited significantly different expressions were identified by 
peptide mass fingerprinting and validated by Western blotting and RT-PCR. The protein 
changes were then correlated to the different grades of disease differentiation. Compared to 
those in adjacent normal epitheliums, the expression of 15 proteins including enolase, 
elongation factor Tu, isocitrate dehydrogenase (NADP), tubulin alpha-1 chain, tubulin beta-5 
chain, actin (cytoplasmic 1),  glyceraldehyde-3 phosphate dehydrogenase (GAPDH), 
tropomyosin isoform 4 (TPM4), prohibitin, peroxiredoxin 1 (PRX1), manganese-containing 
superoxied dismutase (MnSOD), neuronal protein and transgelin were up-regulated and the 
expression of 5 proteins including tropomyosin 1 (TPM1), squamous cell carcinoma antigen 
1 (SCCA1), stratifin, peroxiredoxin 2 isoform a (PRX2) and alpha B crystalline (αB-Cryst) 
were down-regulated in cancer tissues with a statistical significance (p<0.05). In addition, the 
differential expression of SCCA1, PRX1, MnSOD, TPM4 and prohibitin can be observed in 
precancerous lesions of ESCC. The expression of stratifin, prohibitin and SCCA1 dropped 
with increasing dedifferentiation of ESCC. These data may suggest that these proteins 
contribute to the multistage process of carcinogenesis, tumor progression and invasiveness of 
ESCC.  
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1. Introduction 
  Esophageal squamous cell carcinoma (ESCC), the predominant histological subtype of 
esophageal cancer, is the fourth most common malignancy and still represents a great health 
concern in China. The incidence of ESCC is characterized by the striking geographic 
variation in incidence throughout the world [1, 2]. Linzhou (formerly Linxian) and Huixian, 
which geologically belong to Taihang Mountain region in northern China, have the highest 
incidence of ESCC in the world, with an incidence rate of approximately 150 per 100,000 
population [1]. Most of the patients cannot survive more than one year after presenting at 
healthcare centers and the 5-year survival rate for ESCC remains as low as 10 percent or even 
less due to complications caused by the aberrant tumor growth in the esophagus, such as 
dysphagia, cachexia, etc [3, 4]. One of the main reasons for the ominous phenomena is that 
neoplasms in esophagus are not detected until they have invaded the surrounding tissues or 
spread throughout the body at advanced stages. The early detection and diagnosis of 
esophageal malignancy is critical for its therapy and management. 
 A large number of epidemiological studies suggested that cigarette smoking, alcohol 
drinking, diets deficiency in vitamins and/or protective antioxidants, thermal injuries caused 
by hot food, intake of nitrosamine or moldy foodstuff which contain direct or indirect 
carcinogen have been closely correlated to the prevalence of the esophageal cancer [5-7]. The 
etiological factors for ESCC, however, have yet to be clarified. Similar to other types of 
cancer, ESCC involves a multistage process, featuring a great diversity of genetic and 
epigenetic alternations. Although various molecular events and morphologic features have 
been found to closely correlate with malignancies of esophagus, the biomarkers for early 
detection and diagnosis with high specificity and sensitivity and indices for treatment and 
management of esophageal malignancy have not been identified. 
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 Proteomics provides an effective approach to study disease pathogenesis by globally 
examining the different protein expressions due to malignant cell transformation in disease [8, 
9]. Proteomic technology has been successfully applied to identify tumor-associated proteins 
in various cancers originating from different organs including liver [10], lung [11], prostate 
[12], breast [13], kidney [14], tongue [15], buccal mucosa [16] esophagus [17], bladder [18], 
and cholangiole [19]. In this study, we employed proteomics to analyze ESCC tumor 
specimens recruited from Linzhou, China, to identify the proteins with significantly different 
expressions in cancer. The expression patterns of the proteins were then correlated to the 
different stages of malignancy and differentiation status of the disease.  The present findings 
may shed light on the molecular characterization of esophageal cancer progression and may 
be informative for identifying biomarkers and therapeutic targets for ESCC. 
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2. Materials and Methods 
2.1 Tissue specimen 
 Tissues used in this experiment were obtained with the approval of the Committees for 
Ethical Review of Research involving Human Subjects at Zhengzhou University and the 
University of Hong Kong. A total of 17 human ESCC specimens were collected immediately 
after isolation of surgically resected tissues from patients in Linzhou in northern China. The 
17 cases include 10 males and 7 females with averaged age of 60.2 ± 7.3 years. Tissue 
samples were snap-frozen in liquid nitrogen and then preserved in -80oC deep freezer or on 
dry ice for transfer before experiments. The histology for all 17 samples was confirmed by 
two independent histopathologist following fixation, embedding, sectioning and H&E 
staining. All samples comprised more than 80% of target cells (normal epithelial cells, cells 
with various grades of disease or cancer cells) without necrosis. These 17 cases were divided 
into two groups (Table 1). Group 1 contains 15 pairs of intra-matched tissue specimens, i.e., 
tumor center tissues and matched normal esophageal epitheliums at least 5 cm distal from 
primary tumor mass of ESCC. Group 2 has two cases; each contains matched triplet samples 
including tumor and two pre-tumor lesions at different stages based on Lugol’s staining (see 
below).  
2.2 Preparation of tissue protein samples 
 Fresh frozen esophageal tissue samples (100-150 mg) were cut into small pieces, 
dissolved in lysis buffer at the ratio of 1 mg tissue per 2 µl lysis buffer (Reagent 3, Bio-Rad 
Laboratories, Hercules, CA, USA) containing protease inhibitor cocktail (Sigma, St. Louis, 
MO, USA) 8340 and DNase I 1 unit / ml and then homogenized for 5 min on ice with a mini-
homogenizer. The mixture was centrifuged at 13.2 × 1000 rpm at 4oC for 15 min to remove 
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tissue and cell debris. The supernatant was taken as extracted proteins and the protein 
concentration was determined by the Bradford method with BSA as standard. Aliquots of 
protein samples were kept in -80oC deep-freezer until further use. 
 
2.3 2DE electrophoresis, silver staining and image analysis 
 Isoelectronic focusing was conducted using Amersham Biosystems IPG-phor. IPG 
strips with a linear pH range of 3 to 10 were used for protein separation by following a 
protocol described previously [15, 20]. Proteins of 30 to 50 µg for analytical gels and 100 to 
200 µg for preparative gels were utilized for IEF and subsequent second dimensional 
separation.  All samples were run at least in duplicate to guarantee reproducibility. Two good 
quality gels for each case were included into the subsequent image analysis. Silver staining 
was performed as previously described [15]. Images of 2D-gels were digitalized with 
ImageScanner (Amersham Biosciences). Image analyses were conducted with ImageMaster 
2D Elite software 4.01 (Amersham Biosciences) [15]. The normalized value for each protein 
spot volume was used for comparison. Only those spots that have statistical significance in 
differential expression were selected for further investigation.  
2.4 In-gel digestion by trypsin 
 Spots of interest were cut off with a clean scalpel after the preparative gels were washed 
with Mili-Q water and transferred to a siliconized Eppendorf tube. Stained gel slabs were cut 
into 1x1 mm pieces and de-stained with 1 ml of 1:1 (v/v) mixture of 30 mM potassium 
ferricyanide and 100 mM sodium thiosulfate for 10 min and rinsed at least twice with Mili-Q 
water (1ml for 5 min each) until the yellow color disappeared. The gel slabs were equilibrated 
with 0.5 ml of 50 mM NH4HCO3 for 10 min and then incubated with 0.5 ml of 1:1 mixture of 
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50 mM NH4HCO3 and 100% acetonitrile (ACN) for 30 min. Complete dehydration was 
achieved by incubation of gel slabs with 200 µl of 100% ACN and then gel pieces were dried 
in a Speed-Vac for 20 min. For the in-gel digestion, the gel particles were rehydrated with a 
minimal volume of trypsin solution (10 µg/mL in 25 mM NH4HCO3) and incubated at 37oC 
overnight. The liquid fraction containing digested peptides was spotted onto a sample plate 
with equal amounts of matrix. Where necessary, the in-gel digests were extracted 
subsequently with 50% and 80% acetonitrile, and then concentrated and de-salted by Zip tips 
prior to applying on the sample plate [20]. 
2.5 MALDI-TOF MS and protein identification by peptide fingerprinting 
 A Voyage-DE STR MALDI-TOF mass spectrometer (Applied Biosystems, Foster City, 
CA, USA) was employed to obtain the peptide mass spectra with the following settings: 
reflector mode with 175ns delay extraction time, 60-65% grid voltage and 20kV accelerating 
voltage. Laser shots of 250 per spectrum were used to acquire the spectra with mass range of 
500-4000 Da. Mass calibration was performed by using autolytic fragment peaks of trypsin 
including 906.5049, 1153.5741 and 2163.0570 Da. Proteins were identified by peptide 
fingerprinting using MS-Fit to search the NCBInr protein database 
(http://prospector.ucsf.edu). The criteria for database matching are: ±25 ppm mass tolerance, 
at least four peptides matched, and corresponding molecular weights and pI values. The 
species of origin was restricted to Homo Sapiens. 
2.6 Western blotting 
 With reference to the verification of candidate proteins after peptide fingerprinting, the 
proteins of interest were selected for Western blotting to confirm the results of protein 
database searching. After 1D or 2D electrophoresis, proteins were transferred onto PVDF 
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membranes (Amersham Biosciences) at 0.8 mA per cm2 for 1 h. After blocking in 5% non-fat 
milk in TBS-T containing 0.1% Tween 20 (Sigma) at 4oC overnight with gentle rocking, 
membranes were probed with antibodies. Primary antibodies involved in this study include 
SCCA1 (SCCA1 8H11: sc-21767, Santa Cruz Biotechnology, Int.) diluted in 1:250, crystallin 
(SPA-223, Stressgen Biotechnologies) diluted in 1:2000, tropomyosin (TM311, Sigma) 
diluted in 1:400. Membranes were incubated with corresponding primary antibody for 
various durations according to the specificity and sensitivity of antibody. After incubation 
with corresponding secondary antibodies, immunoblots were visualized with the ECL 
detection kit (Amersham biosciences, Sweden, Uppsala). For re-probing membranes with 
another antibody, the membranes were stripped with stripping buffer (glycine 3.75 g/L, SDS 
2 g/L, pH 2.0) before blocking.  
2.7 RNA isolation and RT-PCR 
 TRIZOL Reagent (GIBCOBRL, Life technologies, U.S.A) was used to isolate total 
RNA from frozen tissue samples according to protocol provided by supplier. Reverse 
transcription was performed using 3 µg of extracted total RNA mixed with reaction mixture 
in a final concentration of 0.5 mM dNTPs, 0.025 µg/µl oligo dT, 5 mM MgCl2, 0.01 M DTT, 
2 U/µl RNaseOUTTM inhibitor and 2.5 U/µl SSII RT. The reaction was achieved by 
incubating each sample at 65°C for 5 min, placing on ice for 1 min, incubating at 42°C for 2 
min, mixing with SSII RT followed by incubating at 42°C for 1 hour, and incubating at 70°C 
for 15 min to stop reaction. Following RT, PCR was carried out in a reaction volume of 30 µl 
with final concentration of 1.5 mM MgCl2, 0.1 mM dNTPs, 0.05 Taq DNA Polymerase and 
primer pair for SCCA1. Beta-actin was used for internal normalization. The primer used for 
SCCA1 and beta-actin are listed as follows. The reaction was initiated at 94°C for 10 min 
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followed by 35 cycles at 94°C for 30 s, 55°C for 1 min and 72°C for 1 min, and final 
extension at 72°C for 10 min. 
SCCA1, sense primer 5’ GATTAAGAAGGTTCTTCACTTTGA 3’, antisense primer 5’-
ATGTGGTATTGCTGCCAATATTACCTTCAGGAAT -3’; 
Beta-actin, sense primer, 5’-GTGGGGCGCCCCAGGCACCA-3’, antisense primer 
5’CTCCTTAATGTCACGCACGATTTC 3’. 
2.8 Statistical analysis 
 Since there are only two cases in group 2, the statistical analysis was performed only for 
the 15 paired samples in group 1. Comparison was made between 15 normal samples and 15 
SCC tumor samples regardless their differentiation states. One-tailed Student’s t-test was 
used for statistically analyzing the data extracted from comparison window of ImageMaster 
software that displayed the normalized volumes for each protein spot. A value of  p<0.05 was 
considered significant. 
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3. Results  
3.1 Histological diagnosis of ESCC specimens 
 As shown in Figure 1 & Table 1, two groups of tissue specimens were classified 
through detailed histological diagnosis. For the group 1, the 15 matched SCC tumor tissues 
can be further characterized according to their differentiations into three subgroups, including 
1 well-differentiated, 5 moderately-differentiated and 9 poorly-differentiated SCC.  The 
presence of ESCC and intra-matched epithelium were confirmed by subsequent histological 
examination in which tissue section slides were stained with hematoxylin and eosin (Fig. 1). 
For the group 2, Lugol’s staining was performed before dissecting tissue specimens harboring 
precursor lesions of ESCC. Lugol’s staining is a well-known procedure to screen out diseased 
conditions or precursor lesions of tumors originating from squamous epithelium, such as 
cervix of uterus and esophageal epithelium. Besides the cancer mass, adjacent non-stained 
and stained areas of esophageal epithelium in Lugol’s staining were dissected. The non-
staining area of esophageal mucosae was considered to be precursor lesions for ESCC. As 
listed in the group 2 in Table 1, Case 23 comprised tissues of dysplasia (DYS), carcinoma in 
situ (CIS) and moderately-differentiated SCC; and Case 29 consisted of tissues of basal cell 
hyperproliferation (BCH), DYS and moderately-differentiated SCC, respectively (Fig. 1).  
3.2 2DE protein separation and image analysis 
 Two-dimensional electrophoresis using immobilized pH gradient (linear) ranging from 
3 to 10 was performed to separate the proteins extracted from tumor and adjacent normal 
mucosa or precancerous tissue samples. Figure 2 shows one representative pair of proteome 
profilings for cancer (A) vs. normal (B) tissue samples. There were around 942 spots 
unambiguously displayed on the 2D-gels according to the image analysis using software 
ImageMaster 2D Elite. We found that most of the spots correlated well between 2D maps of 
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cancer and adjacent non-tumor tissues. One-tailed Student’s test was utilized to select the 
protein spots that showed significantly and consistently differences in expression through the 
intra-paired comparative analysis in ImageMaster. 24 protein spots were revealed to have 
differential expressions between cancer tissues and adjacent normal esophageal epitheliums 
with p values less than 0.05 (Table 2). Among these protein spots, 19 were up-regulated and 
5 were significantly down-regulated in ESCC tumor. The numbers denoted on the 2DE maps 
in Figure 2 represent these protein spots; the supposed positions of the spots absent or 
undetectable on one image but present on its counterpart gel are also indicated. The most 
substantial volume change is for spot 808, corresponding to a transgelin isoform, showing an 
averaged expression of 107-folds more in cancer tissues than in non-tumor tissues. In fact, for 
all the 17 paired cases, spot 808 was unequivocally displayed in 13 tumor cases but almost 
undetectable in the 2DE maps of normal tissues or tissues with precursor lesions of ESCC 
(Figure 3).  
3.3 Protein identification by peptide mass fingerprinting 
 Protein spots with statistically consistent and significant differences in protein 
expression were exercised, subjected to in-gel tryptic digestion, MALDI-TOF mass spectral 
measurements and peptide mass fingerprinting to obtain protein IDs. Table 3 lists the 
identified protein IDs, together with corresponding spot numbers, molecular weights and pI 
values, peptides matched, sequence coverages, total mass errors, and MOWSE scores. For 
most of protein database matching, reasonable sequence coverage, low mass errors and high 
MOWSE scores were obtained. Proteins showing over-expressions in tumor are enolase, 
elongation factor Tu, isocitrate dehydrogenase (NADP), tubulin alpha-1 chain, tubulin beta-5 
chain, actin (cytoplasmic 1),  glyceraldehyde-3 phosphate dehydrogenase (GAPDH), 
tropomyosin isoform 4 (TPM4), prohibitin, peroxiredoxin 1 (PRX1), manganese-containing 
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superoxied dismutase (MnSOD), neuronal protein and transgelin. Proteins that were down-
regulated in tumor include tropomyosin 1 (TPM1), squamous cell carcinoma antigen 1 
(SCCA1), stratifin, peroxiredoxin 2 isoform a (PRX2) and alpha B crystalline (αB-Cryst). 
Apparently different protein isoforms existed on proteomic profiling due to alternative 
splicing or post-translation modification. Proteins displaying isoforms are transgelin, 
GAPDH and alpha enolase.  
3.4 Correlation of protein expression with histological grades of ESCC  
 The expression levels of the altered proteins were further correlated to the 
differentiation status of ESCC in Group 1. As depicted in Figure 4, we found that the 
expression changes for protein spots 376 (SCCA1), 586 (Stratifin) and 592 (Prohibitin) 
inversely correlate with differentiation grades of ESCC. The protein expression levels 
decreased with increasing dedifferentiation of ESCC from well-, to moderately- to poorly-
differentiated carcinoma.  
 Detailed protein expression analysis was also carried out for Group 2 that contains two 
matched triplets of specimens from the same patients. Figure 5 shows consistent correlation 
or tendency relationships between lesion grades and protein expressions in the two cases. 
Clearly, expression levels of protein spots 534 (TPM4), 592 (Prohibitin), 701 (PRX1) and 
706 (MnSOD) linearly increased with progression of disease in the precancerous lesions from 
DYS to CIS (case 23) and from BCH to DYS (case 29) advancing to SCC. In addition, 
protein spot 376 (SCCA1) changed its expression level in reverse with the disease severity, 
consistent with the tendency found in Group 1. A negative linear relationship in terms of 
SCCA1 expression levels versus the general trend of disease aggravation can be derived. 
These protein alterations in expression reflect the dynamic molecular characterization of 
esophageal carcinogenesis.  
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3.5 Protein ID and expression confirmation by Western blotting 
 Western blotting was performed to verify three selected proteins, SCCA1, TPM1 and 
αB-Cryst, that may play functional roles in tumorigenesis. Figure 6 shows the 2D Western 
blotting results with the corresponding silver staining 2D-gels side by side for the three 
proteins. Specific and positive immunochemical interactions occurred for the three proteins 
evaluated. Figure 7A displays the representative gels of 1D Western blotting, confirming the 
decreased expressions of these three proteins in tumor tissues. Western blotting results shown 
in Figure 7B exhibit the expression levels of SCCA1, the disease antigen, in the precancerous 
lesions in the specimens of Group 2. In light with the data generated from the 2D-gel image 
analysis, SCCA1 expression levels in tissues decreased from DYS → CIS → SCC (case 23) 
and from BCH → DYS → SCC (case 29), reversely correlated to the aggravation states of 
the ESCC disease. 
3.6 RT-PCR 
 To further verify the unusual expression of SCCA1 in transcription level, RT-PCR 
experiment was performed to compare the mRNA levels in tumor and non-tumor tissues.  
Figure 8 shows the RT-PCR results for three representative pairs of the tissue samples. With 
the mRNA of beta-actin as internal control, the mRNA levels in non-tumor tissues are 
obviously higher than those in tumor tissues, suggesting that the different expression of 
SCCA1 takes place at transcription stage.  
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4. Discussion 
 Although numerous studies in genomic field have revealed a magnitude of changes 
occurring in the multistage pathogenesis of ESCC, including mutations of a variety of tumor 
suppressor genes and oncogenes, changes in transcription, proliferation-associated factors 
and metastasis-related factors, these changes may not necessarily warrant subsequent 
corresponding alternations at the protein levels or functions [21-30]. Proteomics, which aims 
at characterizing the entire protein complement expressed in cells or tissues, provides 
complementary information and direct evidences to unravel tumor-specific molecular events 
during multistage carcinogenesis. In the present study, we used 2DE based proteomics to 
examine the protein profiles of cancer tissues and the adjacent non-tumor tissues freshly 
collected from Linzhou, the highest ESCC incident area in northern China, to identify 
proteins related to esophageal malignancy. A total of 20 proteins were uncovered with 
differential expressions in esophageal carcinogenesis, among which 15 were up-regulated and 
5 were down-regulated. 
 The first intriguing identification is SCC antigen, SCCA1, which was found under-
expressed in ESCC. Initially isolated from human cervical SCC tissue [31], SCCA belongs to 
a serine protease inhibitor family (serpins). Serpins were found to be involved in a variety of 
biological functions, including fibrinolysis, coagulation, inflammation, tumor cell invasion, 
cellular differentiation and apoptosis [32]. Biological studies have revealed that SCCA1 may 
function in cancer cells for tumor growth, and in normal squamous epithelium for 
differentiation by inhibiting apoptosis [33]. The SCC antigen was found highly upregulated 
in various SCC cancers including those in the uterine cervix, lung, head and neck, skin [33, 
34] and recently in buccal mucosa [16]; this protein was therefore regarded as a SCC tumor 
marker. However, we observed that SCCA1 expression in ESCC cancer tissues was 
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suppressed by 2.5 folds compared to adjacent normal tissues (Table 1). This unusual 
observation was further validated by Western blotting data, showing that the under-
expression of SCCA1 not only takes place in tumor tissues in general (Fig. 7A) but also 
proceeds correlatively with malignant potential (Fig. 7B). A similar trend of SCCA1 down-
regulation in ESCC tumor was found in RT-PCR experiment (Fig. 8), suggesting its firm 
occurrence in transcription level. This finding, although contradictory to the results from 
previous studies with other SCC cancers, implicates that the SCCA1 may have a unique 
function in esophagus SCC tumorigenesis. In addition, the decreased expression of SCCA1 
can be linearly correlated to the differentiation progression of the disease in Group 1 (Fig. 4). 
This finding is consistent well with early observations that patients with well-differentiated 
esophageal tumors tended to have higher SCCA1 levels compared to those with poorly 
differentiated tumors [35, 36]. Therefore, it is likely that SCCA1 is an indicator for the 
histological differentiation of the ESCC [37].  
 A group of cytoskeleton microfilaments-associated proteins, including cytoplasmic 
actin, gamma-actin, transgelin, TPM1, TPM4, tubulin alpha-1 chain and tubulin beta-5 chain, 
were found to express differentially between cancer and normal tissues. Actin network is 
essential for cellular functions such as motility, division and cell surface receptor movement, 
anchorage dependence, and contact inhibition. During malignant transformation, expression 
alternations in actin microfilament network and other actin-associated proteins always 
accompany morphological changes [38-41]. Previous studies have demonstrated that 
expression changes in cytoskeleton-associated proteins, including actin, TPM, gelsolin, 
caldesmon, myosin light chain, have been implicated in transformed phenotypes [41]. 
 Tropomyosin (TPM) is a major structural component of cytoskeletal microfilament and 
multiple TPM isoforms have been reported in cultured non-muscle cells. Interestingly, 
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opposite expression regulations for different TPM isoforms have been often found in tumors, 
implying that these isoforms may have different functions in cell transformation. For example, 
under-expressions of high MW TPM have been reported in various cancers such as oral 
tongue squamous cell carcinoma [15], breast [39, 42] and colon [42] cancers. Up-regulation 
of lower MW TPM isoforms has been implicated to be associated with metastatic potential of 
primary breast carcinoma [43], melanoma [44] and Lewis lung carcinoma [45]. Our current 
data validated the different regulations of TPM isoforms, with TPM1 being down-regulated 
and TPM4 being up-regulated significantly in ESCC tissues. The reverse regulation changes 
of TPM isoforms may cause an imbalance in normal phenotypes of epithelial microfilament 
and lead to malignant morphological changes of aberrant cells.  These alterations may 
provide clues related to early detection and diagnosis and to the identification of therapeutic 
targets. 
 Transgelin is another cytoskeleton-associated protein related to cell transformation, 
division, adherence and migration.  Contradictory results concerning transgelin expression in 
tumors have been reported. For example, a proteomic analysis of matched normal 
ductal/lobular units and ductal carcinoma in situ (DCIS) of the human breast revealed that 
transgelin expression was at higher level in normal ductal epithelial cells than in DCIS cells 
[13]. Transgelin gene expression at mRNA level was greatly reduced or lost in transformed 
and tumor cell lines [42]. However, a recent protein profile study discovered that transgelin 
was over-expressed in stomach cancer tissue [46]. Our current observation testified that 
transgelin expression was dramatically increased in ESCC, with a phenomenon that one 
distinct transgelin isoform (spot 808) presents exclusively in the cancer tissues (Fig. 3). 
Given the fact that esophagus and stomach are closely related in digestive tract, ESCC and 
stomach cancer may be subjected to a similar stimulation in term of cell malignant 
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transformation related to transgelin expression. The underlying nature of transgelin functions 
in the tumorigenesis of esophagus and stomach warrants further investigation. 
 Accumulating evidence has indicated that intracellular redox state plays important roles 
in cellular signal transduction and gene expression [47]. Reactive oxygen species (ROS), 
which are produced in cells during physiological processes in response to external stimuli, 
can affect intracellular redox state. At low levels, ROS modulate gene expression through 
modulating cellular redox state; at high levels, ROS are highly deleterious and potentially 
damage DNA, proteins, carbohydrates and lipids. It has been suggested that ROS play roles 
in all stages of carcinogenesis, including initiation, promotion, and progression [48]. In order 
to protect themselves from oxidative radical stress, cells have developed defense systems that 
comprise proteins superoxide dismutases (SOD), catatalse, glutathione peroxidases, and 
preoxiredoxins (PRX). The up-regulations of MnSOD and PRX1 in ESCC and their linear 
correlations with progression of disease from pre-malignant to invasive cancer (Fig. 5) reflect 
the cell defense effort in maintaining intracellular homeostasis. Similar observations have 
been found in other cancers including the over-expression of PRX in malignant mesothelioma 
[49], lung cancer [50] and oral cancer [51], and over-expression of MnSOD in human 
prostate cancer cell lines [52] and in buccal SCC [16]. Interestingly, a minor down-regulation 
of PRX2 isoform was detected in ESCC, suggesting that different PRX isoforms may have 
slightly different functions unique to the esophageal neoplasms. 
 Alpha B crystalline is a member of small heat shock proteins (HSPs) which are 
ubiquitous chaperon molecules related to stresses. They can protect cells from damage 
through binding to partially denatured proteins, dissociating protein aggregates, modulating 
the correct folding, and cooperating in transporting newly synthesized polypeptides to the 
target organelles [53]. αB-Cryst was able to inhibit both the mitochondrial and death receptor 
 18
apoptotic pathways through abolishing the autoproteolytic maturation of partially processed 
caspase-3 intermediate [54]. Intriguingly, while other HSPs were usually up-regulated in 
tumors, αB-Cryst was often down-regulated in various cancers [15, 55-59]. Our present data 
reinforced this observation with αB-Cryst being markedly suppressed in ESCC tissues. These 
results again revealed that αB-Cryst plays a role distinctive from other HSPs in 
carcinogenesis and implicated that under-expression of αB-Cryst may be a general marker 
for various tumors.  
 Stratifin, also known as 14-3-3σ or HME-1, was recently reported to be a candidate 
tumor suppressor gene that is transactivated by p53 in response to DNA damage and 
negatively regulates both G1/S and G2/M cell cycle progression [60, 61]. Over-expression of 
stratifin increased stabilization of p53 through blocking Mdm2-mediated p53 ubiquitination 
and enhanced oligomerization of p53, leading to an increase in p53 transcriptional activity 
[62]. Several studies have reported the potent role of stratifin in tumorigenesis of various 
organs, including prostate, urinary bladder, and breast [18, 63, 64]. In line with other 
published data, a small but significant under-expression of stratifin was found in cancer 
tissues in the present study, implicating its probable contribution to pathogenesis of 
esophageal neoplasms. Additionally, the stratifin expression was inversely correlated with 
differentiation grade of ESCC (Fig. 4), indicating that malignant cells arising from 
esophageal epithelium may lose stratifin in progressive dedifferentiation. 
 Another potential tumor suppressor protein, prohibitin was revealed to be differentially 
expressed between cancer tissue and adjacent normal epithelium. Interestingly, prohibitin 
expression positively correlated with the progression of precancerous lesions (Fig. 5) but 
inversely correlated with the differentiation grades of squamous cell carcinoma of esophagus 
(Fig 4). This expression manner indicates that prohibitin may play different roles at different 
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stages of esophageal tumorigenesis by acting on cell proliferation. One study using RNA 
interference to knock down prohibitin and using transient transfection to over-express the 
protein demonstrated that cells with reduced prohibitin displayed a slight increase in the 
percentage of cell population in cell cycle, while cells with increased prohibitin showed a 
clear reduction in the percentage entering cell cycle following dihydrotestosterone 
stimulation [65]. 
 In summary, we used 2D-gel based proteomics to compare the protein profiles between 
ESCC tumor and matched surrounding tissues and to identify differently expressed proteins 
in the esophageal cancer. A number of tumor-associated proteins including SCCA1, 
transgelin, TPM, prohibitin, PRX, αB-Cryst and MnSOD was detected with altered 
expressions, corresponding to a complicated multi-step process involved in the initiation, 
formation and progression of esophageal carcinoma. When the expressions of the proteins 
were correlated with the histological stages and differentiation status of ESCC tissues, linear 
progressions were found for most of the altered proteins, providing a rational to understand 
the relationships between the functions of the tumor-associated proteins and the cell 
malignant transformation in esophageal tumorigenesis. 
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Table 1 Histopathological classification of ESCC specimens used for 2D-gel proteomic 
analysis.  
  Control & Pre-tumor SCC 
  Normal BCH DYS CIS Well Moderate Poor 
Group 1  15 - - - 1 5 9 
Group 2 Case 23 
Case 29 
- 
- 
- 
1 
1 
1 
1 
- 
- 
- 
1 
1 
- 
- 
 
Normal, normal esophageal epithelium; BCH, basal cell hyperplasia; DYS, dysplasia; CIS, 
carcinoma in situ; SCC, squamous cell carcinoma; Well, well-differentiated SCC; Moderate, 
moderately-differentiated SCC; Poor, poorly-differentiated SCC. 
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Table 2. Summary of peptide mass fingerprinting and statistical differences and p values for the comparison between normal and cancer tissues. 
Spot No. Protein ID (MW/pI) Experimental 
MW(kDa)/pI 
Peptides 
matched 
Sequence 
coverage (%)
Total mass 
error (ppm)
MOWSE 
score 
Differential 
ratio 
p value 
304 Alpha enolase (47 kDa/6.99) 49 / 7.0 43 74 15.6 3.73e+12 +1.8 9.191E-05 
309 Alpha enolase (47 kDa/6.99) 49 / 6.5 27 57 20 3.87e+07 +1.7 0.0018 
310 Alpha enolase (47 kDa/7.0) 49 / 6.8 44 67 17.4 1.74e+13 +1.7 0.0001 
344 Elongation factor Tu (P43) (45 kDa/6.31) 48 / 6.5 10 16 18.8 301 +2.0 0.0081 
349 Isocitrate dehydrogenase [NADP] cytoplasmic (46.7 
kDa/6.53) 
48 / 6.5 29 61 21.4 1.01e+08 +2.1 0.0005 
376 SCCA1  (45kDa/6.3) 46 / 6.5 25 71 16.1 2.46e+07 -2.5 6.474E-06 
386 Tropomyosin 1 (34 kDa/4.9) 37 / 4.6 13 45 11 729 -1.7 0.0066 
456 Tubulin alpha-1 chain and actin cytoplasmic 1 50 kDa/4.94) 40 / 4.8 9 21 10.3 5.90e+05 +4.0 4.394E-06 
484 Tubulin beta-5 chain (50 kDa/4.78) 50 /4.8 9 26 25.4 1450 +5.2 0.0105 
512 Glyceraldehyde 3-phosphate dehydrogenase (36 kDa/8.58) 35 / 8.0 6 19 16.1 234 +1.8 0.0028 
534 Tropomyosin 4 (27.5 kDa/4.8) 37 / 4.5 35 66 18.3 3.07e+04 +2.7 0.0109 
536 Gamma-actin (41.7 kDa/5.3) 39 / 5.0 10 24 13.2 1.08e+04 +2.5 0.0001 
538 Glyceraldehyde 3-phosphate dehydrogenase (36 kDa/8.6) 35 / 8.5 16 47 14.2 2.60e+04 +5.3 8.882E-06 
546 Glyceraldehyde 3-phosphate dehydrogenase (36 kDa/8.6) 35 / 8.5 10 25 24.5 1005 +2.1 0.0133 
550 Tropomyosin isoform (29 kDa/4.8) 37 / 4.5 13 56 18.5 1383 +2.0 0.0029 
586 Stratifin (28kDa/4.7) 28 / 4.5 8 36 14.1 167 -1.5 0.0211 
592 Prohibitin (30 kDa/5.6) 29 / 5.5 10 29 12.9 2131 +1.5 0.0075 
701 Peroxiedoxin 1 (22 kDa/8.3) 24 / 8.0 17 51 16.4 7.73e+06 +2.5 0.0003 
706 Manganese-containing superoxied dismutase (23.7 kDa/6.9) 24 / 7.0 12 57 19.9 1.60e+05 +1.7 0.0015 
714 Peroxiredoxin 2 (22 kDa/5.7) 23 / 5.5 6 25 9.4 281 -1.5 0.0350 
743 Alpha B crystalline (21 kDa/6.7) 21 / 7.0 8 34 33.3 2530 -5.9 0.0020 
795 Neuronal protein (31.5 kDa/8.1) 20 / 8.1 6 23 23.3 597 +4.2 9.276E-05 
806 Transgelin (SM22-alpha)  (22.6 kDa/8.9) 20 / 8.5 18 49 12.7 6.13e+04 +2.42 0.0024 
808 Transgelin (SM22-alpha)  (22.6 kDa/8.9)  20 / 8.6 16 63 18.8 1.55e+04 +107 0.0009 
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Figure Legends 
 
Figure 1.  Representative histology of normal esophageal epithelium, basal cell hyperplasia 
(BCH), dysplasia (DYS), carcinoma in situ (CIS), and esophageal squamous cell carcinoma 
(SCC). Normal esophageal epithelium displays basal membrane, basal cells 1 to 3 layers 
(arrow head), suprabasal cells 5 to 7 layers and superficial layers; BCH shows more than 3 
layers of proliferation of basal cells (arrow head); DYS features loss of architectural 
orientation and comprises deranged cells with various size and shape and large deeply stained 
nuclei; CIS comprises malignant cells occupying the entire thickness of esophageal 
epithelium with intact basal membrane (dotted arrow); SCC comprises numerous malignant 
cells characterized by considerable pleomorphism and mitotic figures (arrow head). 
Figure 2.  Representative images of 2D-gel for cancer (A) verses normal (B) tissue samples, 
respectively. The numbers indicated on map represents protein spots with differential 
expression. 
Figure 3.  Cropped images of protein spots 806 and 808 (Transgelin) in 3 pairs of ESCC 
samples. Transgelin isoform (808) presents exclusively on 2D-gels of cancer tissues.  
Figure 4.  Correlation of protein expression with differentiation status of ESCC. Well, well-
differentiated squamous cell carcinoma; Moderate, moderately-differentiated squamous cell 
carcinoma; Poorly, poorly-differentiated squamous cell carcinoma. Numbers in brackets are 
correlated protein spots on 2D maps. 
Figure 5.  Expression of proteins TPM4, prohibitin, PRX1, and MnSOD in the two cases 
with precancerous lesions. Numbers in brackets represent protein spots on 2D maps. 
Figure 6. Protein confirmation for SCCA1, TPM1 and αB-Cryst by 2D Western blotting. 
Figure 7. Western blots showing the protein expressions for SCCA1, TPM1 and αB-Cryst in 
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tissues (T, tumor; N, normal) of Group 1 (A); and SCCA1 expression in pre-tumorous tissues 
of Group 2 (B).   
Figure 8. RT-PCR results for three representative pairs of tissue samples, showing that the 
mRNA level of SCCA1 is lower in tumor than that in non-tumor tissues. T, tumor; N, normal. 
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